ScholarIQanswers from OpenAlex & ORCID
Raymonde Busch
ResearcherPublications, citations & collaboration network
Raymonde Busch is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Raymonde Busch have?
ScholarIQindexed works
Raymonde Busch has 209 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Raymonde Busch have?
ScholarIQcitation count
Raymonde Busch has 17,758 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Raymonde Busch?
ScholarIQh-index
Raymonde Busch has an h-index of 65 in OpenAlex.
What is the i10-index of Raymonde Busch?
ScholarIQi10-index
Raymonde Busch has an i10-index of 152 in OpenAlex.
What is the OpenAlex record for Raymonde Busch?
ScholarIQopenalex
The OpenAlex for Raymonde Busch is on the source record.
What are the most-cited papers on Raymonde Busch?
ScholarIQmost cited works
<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael Wenger, Günter Fingerle‐Rowson, Peter Lichter, Mario Cazzola, Clemens‐Martin Wendtner, Anna Maria Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, Sebastian Böttcher, Jasmin Bahlo, Jöerg Schubert, Karl Heinz Pflüger, Silke Schott, Valentin Goede, Susanne Isfort, Julia von Tresckow, Anna‐Maria Fink, Andreas Bühler, Dirk Winkler, Karl‐Anton Kreuzer, Peter Staib, Matthias Ritgen, Michael Kneba, Hartmut Döhner, Barbara Eichhorst, Michael Hallek, Stephan Stilgenbauer, Clemens‐Martin Wendtner
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, Stephan Stilgenbauer, Jasmin Bahlo, Carmen D. Schweighofer, Sebastian Böttcher, Peter Staib, Michael Kiehl, Michael J. Eckart, Gabriele Kranz, Valentin Goede, Thomas Elter, Andreas Bühler, Dirk Winkler, Michael Kneba, Hartmut Döhner, Barbara Eichhorst, Michael Hallek, Clemens‐Martin Wendtner
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Peter Dreger, Hartmut Döhner, Matthias Ritgen, Sebastian Böttcher, Raymonde Busch, Sascha Dietrich, Donald Bunjes, Sandra Cohen, Jörg Schubert, Ute Hegenbart, Dietrich W. Beelen, Matthias Zeis, Michael Stadler, Justin Hasenkamp, Lutz Uharek, Christof Scheid, Andreas Humpe, Thorsten Zenz, Dirk Winkler, Michael Hallek, Michael Kneba, Norbert Schmitz, Stephan Stilgenbauer, for the German CLL Study Group